Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 1517-1524, April 1, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gandhi, V.
Right arrow Articles by Plunkett, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gandhi, V.
Right arrow Articles by Plunkett, W.

Cytotoxicity, Metabolism, and Mechanisms of Action of 2',2'-Difluorodeoxyguanosine in Chinese Hamster Ovary Cells1

Varsha Gandhi2, Shin Mineishi, Peng Huang, Amy J. Chapman, Yandan Yang, Feng Chen, Billie Nowak, Sherri Chubb, Larry W. Hertel and William Plunkett

Department of Clinical Investigation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [V. G., S. M., P. H., A. J. C., Y. Y., F. C., B. N., S. C., W. P.], and Lilly Research Laboratories, Indianapolis, Indiana 46285 (L. W. H.)

The emerging clinical success of gemcitabine (2',2'-difluorodeoxycytidine) stimulated interest in the synthesis and evaluation of purine congeners. The cytotoxicity, metabolism, and mechanisms of action of the lead candidate, 2',2'-difluorodeoxyguanosine (dFdGuo), were studied in Chinese hamster ovary cells. Unlike the natural nucleoside deoxyguanosine (dGuo), dFdGuo was not a substrate for purine nucleoside phosphorylase. Wild-type Chinese hamster ovary cells and a mutant line deficient in deoxycytidine (dCyd) kinase were similarly affected by dFdGuo (50% inhibitory concentration, 7.5 and 6.5 µM, respectively), suggesting that unlike gemcitabine, dCyd kinase was not responsible for activation of dFdGuo. This was further confirmed by separation of nucleoside kinases (adenosine kinase, dGuo kinase, and dCyd kinase) of Chinese hamster ovary cells on DEAE-cellulose column chromatography. The kinase activity that phosphorylated dGuo also converted dFdGuo to its monophosphate, suggesting that dGuo kinase activated dFdGuo. Consistent with this result, coincubation with dGuo spared the dFdGuo-mediated toxicity; however, addition of up to 10 mM dCyd did not reverse the toxicity of dFdGuo. Intracellularly, dFdGuo was phosphorylated to its mono-, di-, and triphosphates; dFdGuo triphosphate (dFdGTP) was the major metabolite and accumulated to 45 µM after a 6-h incubation with 30 µM dFdGuo. The elimination of dFdGTP was monophasic with a t1/2 of about 6 h. Deoxynucleotides were decreased in cells incubated with dFdGuo, suggesting that ribonucleotide reductase was inhibited. dATP, which decreased 78% after a 4-h incubation with 30 µM dFdGuo, was most affected. dFdGuo was a potent inhibitor of DNA synthesis. Extension of a DNA primer over a defined template in the presence of dFdGTP revealed that dFdGTP was a good substrate for incorporation opposite C sites of the template by DNA polymerase {alpha}. dFdGTP incorporation caused DNA polymerase {alpha} to pause after the polymerization of one additional deoxynucleotide. This pattern of inhibition, which is shared by gemcitabine, distinguishes 2',2'-difluoronucleosides from arabinosylnucleosides which halt primer extension at the incorporation site. dGTP competed effectively with dFdGTP for incorporation by DNA polymerase {alpha}. The unique activation requirements and patterns of inhibition of DNA synthesis distinguish this promising new antimetabolite from other nucleoside analogues.

1 Supported in part by Grants CA 28596 and CA 57629 from the National Cancer Institute, Department of Health and Human Services, and Grant DHP-1 from the American Cancer Society.

2 To whom requests for reprints should be addressed, at Department of Clinical Investigation, Box 52, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.

Received 11/29/94. Accepted 2/ 3/95.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
D. F Kisor
Nelarabine: A Nucleoside Analog with Efficacy in T-Cell and Other Leukemias
Ann. Pharmacother., June 1, 2005; 39(6): 1056 - 1063.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Giovannetti, V. Mey, R. Danesi, I. Mosca, and M. Del Tacca
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
Clin. Cancer Res., May 1, 2004; 10(9): 2936 - 2943.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. O. Rodriguez Jr, C. M. Stellrecht, and V. Gandhi
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine
Blood, September 1, 2003; 102(5): 1842 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Leblond, G. Attardo, B. Hamelin, D. Y. Bouffard, N. Nguyen-Ba, and H. Gourdeau
BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: A Cyclic Nucleoside Phosphonate with Antitumor Activity
Mol. Cancer Ther., July 1, 2002; 1(9): 737 - 746.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. O. Rodriguez Jr., B. S. Mitchell, M. Ayres, S. Eriksson, and V. Gandhi
Arabinosylguanine Is Phosphorylated by Both Cytoplasmic Deoxycytidine Kinase and Mitochondrial Deoxyguanosine Kinase
Cancer Res., June 1, 2002; 62(11): 3100 - 3105.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, C. O. Rodriguez Jr, P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, et al.
Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells
J. Clin. Oncol., April 15, 2001; 19(8): 2142 - 2152.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. O. Rodriguez Jr. and V. Gandhi
Arabinosylguanine-induced Apoptosis of T-Lymphoblastic Cells: Incorporation into DNA Is a Necessary Step
Cancer Res., October 1, 1999; 59(19): 4937 - 4943.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Kramata, K. M. Downey, and L. R. Paborsky
Incorporation and Excision of 9-(2-Phosphonylmethoxyethyl)guanine (PMEG) by DNA Polymerase delta  and epsilon  in Vitro
J. Biol. Chem., August 21, 1998; 273(34): 21966 - 21971.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Zhu, M. Johansson, J. Permert, and A. Karlsson
Enhanced Cytotoxicity of Nucleoside Analogs by Overexpression of Mitochondrial Deoxyguanosine Kinase in Cancer Cell Lines
J. Biol. Chem., June 12, 1998; 273(24): 14707 - 14711.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.